Status:
TERMINATED
A Phase II Study of Iressa in Patients With Chemo Refractory Germ Cell Tumors Expressing EGFR
Lead Sponsor:
Indiana University School of Medicine
Collaborating Sponsors:
AstraZeneca
Conditions:
Refractory Germ Cell Tumors Expressing EGRF
Eligibility:
All Genders
15+ years
Phase:
PHASE2
Brief Summary
This study will evaluate the use of ZD1839 in the treatment of subjects with refractory germ cell tumors. Subjects will take ZD1839 for one year in the absence of excessive toxicity or decision to wit...
Detailed Description
The primary objective is to determine the response rate of ZD1839 in patients with refractory germ cell tumors expressing EGFR. The secondary objectives are to determine the duration of response, time...
Eligibility Criteria
Inclusion
- Histologic or serologic proof of metastatic germ cell neoplasm(gonadal or extragonadal primary) with disease not amenable to cure with either surgery or chemotherapy. Patients w/ seminoma and non-seminoma are eligible, as are women w/ ovarian germ cell tumors.
- Evidence of recurrent or metastatic carcinoma
- Must have received initial cisplatin combination therapy \& demonstrated progression following the administration of at least one "salvage" regimen for advanced germ cell neoplasms.
- Patients are eligible after first line platinum bsed chemotherapy if their disease has relapsed and they have primary mediastinal non seminomatous germ cell tumor, late relapse or progressed w/in 4 wks of last platinum dose.
- immunohistochemical documentation of EGFR expression documented.
- adequate organ function: ANC \>/=150,plt \>100K, total bili \</= upper limit of normal(ULN). Pts w/ liver mets up to 3x ULN.Transaminases up to 1.5 x ULN if alk phos is \</=ULN or alk phos may be up to 4x ULN if transaminases are \</= ULN. Pts w/ liver mets may have alk phos up to 5x ULN. Serum crt \</= 2.0.
- ECOG performance status 0-2.
Exclusion
- Must be 3 weeks post major surgery, radiotherapy, or chemotherapy and hae recovered from all toxicity.
- Active unresolved infection and/or are receiving concurrent treatment with parenteral antibiotics are ineligible.
- Patients requiring steroids for symptomatic brain metastasis are not eligible.
- Pregnant or lactating patients are not eligible.
- Class III/IV heart disease
Key Trial Info
Start Date :
September 1 2002
Trial Type :
INTERVENTIONAL
End Date :
March 1 2006
Estimated Enrollment :
21 Patients enrolled
Trial Details
Trial ID
NCT00198159
Start Date
September 1 2002
End Date
March 1 2006
Last Update
September 19 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Indiana University Cancer Center
Indianapolis, Indiana, United States, 46202